G6b-B regulates an essential step in megakaryocyte maturation.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
24 05 2022
24 05 2022
Historique:
received:
14
09
2021
accepted:
20
01
2022
pubmed:
9
2
2022
medline:
25
5
2022
entrez:
8
2
2022
Statut:
ppublish
Résumé
G6b-B is a megakaryocyte lineage-specific immunoreceptor tyrosine-based inhibition motif-containing receptor, essential for platelet homeostasis. Mice with a genomic deletion of the entire Mpig6b locus develop severe macrothrombocytopenia and myelofibrosis, which is reflected in humans with null mutations in MPIG6B. The current model proposes that megakaryocytes lacking G6b-B develop normally, whereas proplatelet release is hampered, but the underlying molecular mechanism remains unclear. We report on a spontaneous recessive single nucleotide mutation in C57BL/6 mice, localized within the intronic region of the Mpig6b locus that abolishes G6b-B expression and reproduces macrothrombocytopenia, myelofibrosis, and osteosclerosis. As the mutation is based on a single-nucleotide exchange, Mpig6bmut mice represent an ideal model to study the role of G6b-B. Megakaryocytes from these mice were smaller, displayed a less-developed demarcation membrane system, and had a reduced expression of receptors. RNA sequencing revealed a striking global reduction in the level of megakaryocyte-specific transcripts, in conjunction with decreased protein levels of the transcription factor GATA-1 and impaired thrombopoietin signaling. The reduced number of mature MKs in the bone marrow was corroborated on a newly developed Mpig6b-null mouse strain. Our findings highlight an unexpected essential role of G6b-B in the early differentiation within the megakaryocytic lineage.
Identifiants
pubmed: 35134123
pii: 483863
doi: 10.1182/bloodadvances.2021006151
pmc: PMC9131916
doi:
Substances chimiques
Nucleotides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3155-3161Informations de copyright
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Eur J Haematol. 2017 Mar;98(3):218-227
pubmed: 27743390
Br J Haematol. 2020 Sep;190(5):e316-e320
pubmed: 32567678
Mol Cell Proteomics. 2007 Mar;6(3):548-64
pubmed: 17186946
Blood. 2002 Aug 15;100(4):1123-32
pubmed: 12149188
J Bone Miner Res. 2004 Apr;19(4):652-60
pubmed: 15005853
Elife. 2019 Aug 22;8:
pubmed: 31436532
Blood. 2020 Apr 30;135(18):1574-1587
pubmed: 32016283
EMBO J. 1997 Jul 1;16(13):3965-73
pubmed: 9233806
Pathol Biol (Paris). 2004 Jun;52(5):275-9
pubmed: 15217713
Blood. 2018 Sep 27;132(13):1399-1412
pubmed: 29898956
Blood. 2013 May 16;121(20):4205-20
pubmed: 23509158
Hematol Oncol Clin North Am. 2021 Apr;35(2):191-203
pubmed: 33641863
J Biol Chem. 2001 Nov 9;276(45):42070-6
pubmed: 11544253
J Biol Chem. 2001 Jan 26;276(4):2494-502
pubmed: 11054408
Pediatr Blood Cancer. 2021 Aug;68(8):e29062
pubmed: 33871931
J Thromb Haemost. 2013 Apr;11(4):593-604
pubmed: 23311859
J Exp Med. 2014 May 5;211(5):909-27
pubmed: 24711581
Cell. 1995 Jun 2;81(5):695-704
pubmed: 7774011
J Thromb Haemost. 2005 Aug;3(8):1717-24
pubmed: 16102038
Blood. 2018 Sep 27;132(13):1413-1425
pubmed: 29891536
Nat Med. 2015 Dec;21(12):1473-80
pubmed: 26569382
J Cell Biol. 2013 Jun 10;201(6):785-96
pubmed: 23751492
Sci Signal. 2012 Oct 30;5(248):ra78
pubmed: 23112346
J Bone Miner Res. 2021 Apr;36(4):803-813
pubmed: 33434328
Blood. 2019 Aug 29;134(9):727-740
pubmed: 31311815
Gene. 2019 Oct 5;715:143957
pubmed: 31276734
Clin Cancer Res. 2019 Aug 15;25(16):4898-4906
pubmed: 31061068
Mediterr J Hematol Infect Dis. 2018 Nov 01;10(1):e2018068
pubmed: 30416700
Cell Rep. 2021 May 11;35(6):109102
pubmed: 33979620